This compound is a conjugated form of the antimitotic agent monomethyl auristatin E (MMAE), linked through a maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate (mc-vc-PAB) spacer. It is primarily used as an intermediate in the manufacturing of antibody-drug conjugates (ADCs), enabling the stable attachment of the cytotoxic payload to targeting antibodies.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 646502-53-6
L-Valinamide, N,N-dimethyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydro xy-1-methyl-
active pharmaceutical ingredient
MMAF
pharmaceutical intermediate
VC-PAB-MMAE
antibody-drug conjugate intermediate
N-(2-BROMO-4,5-DIFLUOROPHENYL)ACETAMIDE
pharmaceutical intermediate
2-azaspiro[4.5]decan-3-one
Pharmaceutical intermediate
1-Bromo-2-methoxyethane
pharmaceutical intermediate
(S)-(+)-2-PHENYLGLYCINE AMIDE
Peptide building block intermediate
Monomethyl auristatin E
pharmaceutical intermediate for antibody-drug conjugate
(2S)-N-[(2S)-1-[[(3R,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
DASWEROEPLKSEI-AWNAIHLBSA-N
CC[C@H](C)C([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC